DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Information source: Oregon Health and Science University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Parkinson's Disease

Intervention: Amantadine 300 mg (Drug); Topiramate (Drug); Sugar Pill (Drug)

Phase: N/A

Status: Terminated

Sponsored by: Oregon Health and Science University

Official(s) and/or principal investigator(s):
Kathryn Chung, MD, Principal Investigator, Affiliation: Oregon Health & Science University, Portland VA Medical Center
John G Nutt, MD, Principal Investigator, Affiliation: Oregon Health & Science Unversity


Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements. To date, there are no objective measures of these movements. The purpose of this study is to measure the reduction of the movements by amantadine and/or topiramate using an objective measure.

Clinical Details

Official title: Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Forceplate Measurement of Dyskinesia

Secondary outcome: Inertial Sensor Signal

Detailed description: Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias) caused by the gold standard treatment, Levodopa. The severity of these movements can range from subtle to extremely debilitating and may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. Currently, one of the very few treatments for these unwanted and involuntary movements is Amantadine. New options to treat dyskinesia would be clinically very valuable. In a previous study, we developed an objective measuring device to quantify dyskinesia. All PD participants will receive all three of the drug treatment intervention (placebo, Amantadine 300 mg, Amantadine 300 mg plus Topiramate 150 mg). After 2 weeks of one drug treatment, the participants will complete an overnight visit at the OCTRI Inpatient unit. During the next day, participants will complete a mental task while standing on a force plate for one minute every half hour until the end of the study. A levodopa IV infusion will occur from 0900 to 1100. The subjects will be split into 'high' and 'low' dose groups. Those who take <50 mg/hour of oral levodopa or levodopa equivalents will be considered 'low' dose subjects and will receive 1 mg/kg/hr of IV Levodopa during the study visits (1, 2, and 3). Those who administer > 50 mg/hr of oral levodopa to themselves normally will be considered 'high' dose subjects and will received 1. 5 mg/kg/hr levodopa. Both groups will

receive the infusion for two hours from 0900 - 1100. The study drug will be taken orally at



Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Parkinson's Disease

- At least 21 years of age

- Must be taking Oral levodopa

- Must have dyskinesias by history or previous clinical observation

Exclusion Criteria:

- Significant cognitive impairment as measured by the Montreal Cognitive Assessment

(MOCA) score of < 25

- Subjects with unstable medical or psychiatric conditions (including hallucinations)

- Use of dopamine receptor blocking medications (e. g., neuroleptics, certain

antiemetics, tetrabenazine)

- History of unstable medical conditions (ie active cardiovascular disease, recent

unwellness or surgery etc.)

- Use of anticoagulants

- Current substance abuse

- Previous adverse event on amantadine

Locations and Contacts

Oregon Health & Science University, Portland, Oregon 97239, United States
Additional Information

Related publications:

Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5.

Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998 May;50(5):1323-6.

Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001 May;16(3):515-20.

Hagell P, Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord. 1999 May;14(3):448-55.

da Silva-JĂșnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord. 2005 Nov;11(7):449-52. Epub 2005 Sep 9.

Starting date: September 2009
Last updated: September 11, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017